JP2011529475A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011529475A5 JP2011529475A5 JP2011520506A JP2011520506A JP2011529475A5 JP 2011529475 A5 JP2011529475 A5 JP 2011529475A5 JP 2011520506 A JP2011520506 A JP 2011520506A JP 2011520506 A JP2011520506 A JP 2011520506A JP 2011529475 A5 JP2011529475 A5 JP 2011529475A5
- Authority
- JP
- Japan
- Prior art keywords
- vaccine
- vlp
- dose
- hpv
- adjuvant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 25
- 229960005486 vaccine Drugs 0.000 claims 22
- 239000002671 adjuvant Substances 0.000 claims 13
- 241000701806 Human papillomavirus Species 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 208000015181 infectious disease Diseases 0.000 claims 6
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical group [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims 4
- 241000341655 Human papillomavirus type 16 Species 0.000 claims 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical group [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims 2
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical class O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8510108P | 2008-07-31 | 2008-07-31 | |
| US61/085,101 | 2008-07-31 | ||
| US17656109P | 2009-05-08 | 2009-05-08 | |
| US61/176,561 | 2009-05-08 | ||
| PCT/EP2009/059820 WO2010012780A1 (en) | 2008-07-31 | 2009-07-29 | Vaccine against hpv |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011529475A JP2011529475A (ja) | 2011-12-08 |
| JP2011529475A5 true JP2011529475A5 (enExample) | 2012-09-13 |
| JP6022159B2 JP6022159B2 (ja) | 2016-11-09 |
Family
ID=41139260
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011520506A Active JP6022159B2 (ja) | 2008-07-31 | 2009-07-29 | 抗ｈｐｖワクチン |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20110189229A1 (enExample) |
| EP (1) | EP2318042B1 (enExample) |
| JP (1) | JP6022159B2 (enExample) |
| KR (1) | KR20110053340A (enExample) |
| CN (1) | CN102159239A (enExample) |
| AU (1) | AU2009275909A1 (enExample) |
| BR (1) | BRPI0916732B1 (enExample) |
| CA (1) | CA2732436C (enExample) |
| CO (1) | CO6341567A2 (enExample) |
| DK (1) | DK2318042T3 (enExample) |
| DO (1) | DOP2011000031A (enExample) |
| EA (1) | EA201170264A1 (enExample) |
| ES (1) | ES2519490T3 (enExample) |
| HR (1) | HRP20141063T1 (enExample) |
| IL (1) | IL210977A0 (enExample) |
| MA (1) | MA32554B1 (enExample) |
| MX (1) | MX2011001218A (enExample) |
| NZ (1) | NZ590919A (enExample) |
| PE (1) | PE20110327A1 (enExample) |
| PL (1) | PL2318042T3 (enExample) |
| PT (1) | PT2318042E (enExample) |
| RS (1) | RS53607B1 (enExample) |
| SI (1) | SI2318042T1 (enExample) |
| SM (1) | SMT201400170B (enExample) |
| WO (1) | WO2010012780A1 (enExample) |
| ZA (1) | ZA201100889B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010264695A1 (en) | 2009-06-25 | 2012-01-19 | Glaxosmithkline Biologicals S.A. | Novel human papillomavirus (HPV) protein constructs and their use in the prevention of HPV disease |
| CN102178944A (zh) * | 2010-09-17 | 2011-09-14 | 大连雅立峰生物制药有限公司 | 人乳头瘤病毒16和18型l1蛋白在昆虫细胞中的表达及应用 |
| CN102229660B (zh) * | 2011-05-25 | 2015-04-22 | 厦门大学 | 截短的人乳头瘤病毒33型l1蛋白 |
| KR101559622B1 (ko) * | 2012-07-30 | 2015-10-13 | 중앙대학교 산학협력단 | 인유두종바이러스 바이러스 유사입자의 고효율 정제방법 |
| AU2015313756A1 (en) * | 2014-09-11 | 2017-03-09 | Cadila Healthcare Limited | Superior human papilloma virus antigens with superior immunological properties and vaccine containing it |
| US10063211B2 (en) | 2016-02-03 | 2018-08-28 | Qualcomm Incorporated | Compact bypass and decoupling structure for millimeter-wave circuits |
| RU2628693C1 (ru) * | 2016-11-10 | 2017-08-21 | федеральное государственное бюджетное учреждение "Федеральный научно-исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации (ФГБУ "ФНИЦЭМ им. Н.Ф. Гамалеи" Минздрава России) | РЕКОМБИНАНТНЫЙ ГЕН L1HPV16, РЕКОМБИНАНТНАЯ ПЛАЗМИДА pQE-L1/16, БЕЛОК L1HPV16 И ИХ ПРИМЕНЕНИЕ |
| US20210302427A1 (en) * | 2020-03-31 | 2021-09-30 | Shuhari Group, LLC | Secure Immunity Information Transmission System And Network |
| WO2025147639A1 (en) * | 2024-01-04 | 2025-07-10 | Cyanvac Llc | Improved formulation providing increased stability for vaccines composition |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9921146D0 (en) * | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
| WO2005089164A2 (en) * | 2003-12-31 | 2005-09-29 | Pharmexa Inc. | Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions |
| US7758866B2 (en) * | 2004-06-16 | 2010-07-20 | Glaxosmithkline Biologicals, S.A. | Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52 |
| WO2005123125A1 (en) * | 2004-06-16 | 2005-12-29 | Glaxosmithkline Biologicals S.A. | Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52 |
| WO2006114312A2 (en) * | 2005-04-26 | 2006-11-02 | Glaxosmithkline Biologicals S.A. | Vaccine |
-
2009
- 2009-07-29 JP JP2011520506A patent/JP6022159B2/ja active Active
- 2009-07-29 AU AU2009275909A patent/AU2009275909A1/en not_active Abandoned
- 2009-07-29 WO PCT/EP2009/059820 patent/WO2010012780A1/en not_active Ceased
- 2009-07-29 PL PL09781248T patent/PL2318042T3/pl unknown
- 2009-07-29 SI SI200931047T patent/SI2318042T1/sl unknown
- 2009-07-29 CA CA2732436A patent/CA2732436C/en active Active
- 2009-07-29 DK DK09781248.1T patent/DK2318042T3/da active
- 2009-07-29 US US13/056,452 patent/US20110189229A1/en not_active Abandoned
- 2009-07-29 KR KR1020117004436A patent/KR20110053340A/ko not_active Withdrawn
- 2009-07-29 MX MX2011001218A patent/MX2011001218A/es not_active Application Discontinuation
- 2009-07-29 EA EA201170264A patent/EA201170264A1/ru unknown
- 2009-07-29 PT PT97812481T patent/PT2318042E/pt unknown
- 2009-07-29 RS RS20140613A patent/RS53607B1/sr unknown
- 2009-07-29 PE PE2011000104A patent/PE20110327A1/es not_active Application Discontinuation
- 2009-07-29 NZ NZ590919A patent/NZ590919A/xx not_active IP Right Cessation
- 2009-07-29 HR HRP20141063AT patent/HRP20141063T1/hr unknown
- 2009-07-29 ES ES09781248.1T patent/ES2519490T3/es active Active
- 2009-07-29 EP EP09781248.1A patent/EP2318042B1/en active Active
- 2009-07-29 BR BRPI0916732-3A patent/BRPI0916732B1/pt active IP Right Grant
- 2009-07-29 CN CN200980135875XA patent/CN102159239A/zh active Pending
-
2011
- 2011-01-28 DO DO2011000031A patent/DOP2011000031A/es unknown
- 2011-01-31 IL IL210977A patent/IL210977A0/en unknown
- 2011-02-03 ZA ZA2011/00889A patent/ZA201100889B/en unknown
- 2011-02-11 MA MA33605A patent/MA32554B1/fr unknown
- 2011-02-23 CO CO11022213A patent/CO6341567A2/es not_active Application Discontinuation
-
2014
- 2014-11-10 SM SM201400170T patent/SMT201400170B/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011529475A5 (enExample) | ||
| JP5956974B2 (ja) | パピローマウイルスワクチン組成物 | |
| HRP20141063T1 (hr) | Cjepivo protiv hpv | |
| HRP20141258T1 (hr) | 6-amino-2-{[(1s)-1-metilbutil]oksi}-9-[5-(1-piperidinil)pentil]-7,9-dihidro-8h-purin-8-on maleat | |
| JP2011225578A5 (enExample) | ||
| JP2012517987A5 (ja) | 吸入用の医薬組成物のｆｐｄ特性を設定する方法 | |
| US11638754B2 (en) | HPV vaccine | |
| EP2444103A4 (en) | UTERUS COLON CANCER VACCINE | |
| US20180236059A1 (en) | Polysaccharide composition and use thereof | |
| US20120045479A1 (en) | Dry Powder Formulations, Vaccines and Methods | |
| WO2024146068A1 (zh) | 雷公藤红素或其可药用衍生物在制备疫苗佐剂中的用途 | |
| JP2013523682A5 (enExample) | ||
| CN105597092A (zh) | 含有白介素15的防治hpv感染的疫苗喷雾剂 | |
| CN103599093B (zh) | 一种抗hpv药物制剂及用途 | |
| RU2006143804A (ru) | Вакцина против вирусов папилломы человека hpv16 и hpv18 и по меньшей мере еще одного типа hpv, выбранного из hpv 31,45 или 52 | |
| JP2011157395A5 (enExample) | ||
| US20230048144A1 (en) | Hpv vaccine | |
| TW202034950A (zh) | 用於治療b型肝炎的藥物製劑及其製備方法和用途 | |
| CN105434631A (zh) | 花椒精油在制备用于预防和/或治疗病毒性流感的药物或保健品中的应用 | |
| US20250205328A1 (en) | Controlled release vaccine formulations | |
| WO2012097634A1 (zh) | 一种治疗hpv感染的药物以及该药物在制备治疗hpv感染药物中的应用 | |
| CN104208664A (zh) | 一种鼻用疫苗组合物液体制剂及其制备方法 | |
| Kim et al. | Human papillomavirus vaccine | |
| Somasundaram | HPV vaccine: End to women's major health problem? | |
| EA047059B1 (ru) | Вакцина против hpv |